Treatment with TQB2930 for advanced breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This exploratory phase Ib/II study investigates the safety and efficacy of TQB2930, both as a monotherapy and in combination with other treatments, for patients with recurrent or metastatic breast cancer. The phase Ib portion focuses on determining the maximum tolerated dose (MTD) and includes dose expansion for monotherapy. The phase II portion evaluates TQB2930 combined with albumin-paclitaxel or other chemotherapy options. The study aims to provide insights into effective treatment options for patients who have not responded to standard therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age: 18-75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0\~1; The expected survival is over 3 months.
* Phase Ib

  1. Advanced malignancies confirmed by cytology / histopathology, priority given to subjects with HER2 expression or amplification;
  2. Subjects with malignant tumors who have failed standard treatment or lack effective treatment;
  3. Confirmed presence of at least one evaluable lesion according to RECIST 1.1 criteria
* Phase II

  1. Hormone receptor (HR)-negative, HER2-positive breast cancer confirmed by cytology / histopathology, with evidence of local recurrence or distant metastasis, unsuitable for surgery or radiotherapy for curative purposes:
  2. Have not received systemic antitumor therapy for metastatic stage; Systemic use of endocrine therapy is permitted, but not exceed 2 lines;
  3. at least one measurable lesion that meets the RECIST 1.1 criteria.
* Major organs are functioning normally.
* Female subjects of reproductive age should agree to use contraceptive methods during the study period and until 6 months after the end of the study; Negative serum pregnancy / urine pregnancy test within 7 days prior to study enrollment and must be non-lactating subjects; Male subjects should agree to use contraception during the study and until six months after the end of the study.

Exclusion Criteria:

* Have occured other malignant tumors within 3 years prior to first dose.
* Unalleviated toxicity above Common Terminology Criteria for Adverse Events (CTCAE) grade 1 due to any prior treatment;
* Received major surgical treatment, open biopsy, or significant traumatic injury within 28 days prior to the first dose;
* Long-term unhealed wounds or fractures;
* Arterial/venous thrombosis events occurred within 6 months before the first dose;
* Have a history of psychotropic drug abuse and can't get rid of it or have mental disorders;
* Subject with any severe and/or uncontrolled disease;
* Subjects who have been treated with other antitumor agents such as chemotherapy, radiotherapy, or immunotherapy within 4 weeks prior to the first dose, within 5 half-lives of the drug;
* Have used traditional chinese medicine with anti-tumor indications approved by National Medical Products Administration (NMPA) within 2 weeks before the first dose;
* Severe bone injury due to bone metastasis;
* Subjects with untreated active brain metastases or meningeal metastases or cancerous meningitis;
* In the course of previous HER2-targeted therapy, Left Ventricular Ejection Fractions (LVEF) decreased to \<50% or absolute LVEF decreased \>15%;
* Cumulative doses of anthracyclines exceeded doxorubicin or doxorubicin liposomes \>360 mg/m2;
* Uncontrolled hypercalcemia or symptomatic hypercalcemia requires continued bisphosphonate therapy
* Patients with severe hypersensitivity after the use of monoclonal antibodies;
* Has participated in other antitumor clinical trials within 4 weeks prior to the first dose.

Where it's running

• Affiliated Cancer Hospital of Chongqing University
  Chongqing, Chongqing Municipality, China Recruiting
• Affiliated cancer hospital of harbin medical university
  Harbin, Heilongjiang, China Recruiting

Study contacts

• Study coordinator: Qingyuan Zhang, Doctor
• Email: sy86298276@163.com
• Phone: +86 0451 86298070

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining bortezomib and cisplatin for advanced breast cancer

  This study is testing if combining two cancer drugs, bortezomib and cisplatin, can help women with advanced breast cancer who haven't had success with other treatments.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong · NCT06900647

• Combining Alisertib with Endocrine Therapy for Advanced Breast Cancer

  This study is testing if adding a targeted therapy called alisertib to hormone treatment can help people with advanced breast cancer who haven’t responded to previous hormone therapies.

  Recruiting at 52 sites Phase 2 Puma Biotechnology, Inc. · Birmingham, Alabama and 52 other locations · NCT06369285

• PRT13722 in advanced HR+/HER2- breast cancer

  This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.

  Recruiting Phase 1 Prelude Therapeutics Incorporated · Maumee, Ohio · NCT07905001

• Personalized treatment after endocrine therapy failure in metastatic breast cancer

  The study tests whether using a patient’s fresh tumor sample to try different drugs outside the body can help pick the next therapy for hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on endocrine therapy.

  Recruiting Tel-Aviv Sourasky Medical Center · Tel Aviv · NCT07895160

• SSGJ-612 plus a HER2-targeted ADC in HR-positive, HER2-low metastatic breast cancer

  This phase II study tests whether adding SSGJ-612 to a HER2-targeted antibody-drug conjugate helps people with HR-positive, HER2-low or ultralow metastatic breast cancer.

  Recruiting Phase 2 Shenyang Sunshine Pharmaceutical Co., LTD. · Guangzhou, Guangdong · NCT07757230

• GPC3-targeted ADC for advanced solid tumors

  This early-phase trial tests a Glypican-3 targeted antibody-drug conjugate (TQB6426) in adults with advanced cancers to see if it is safe and tolerable and to explore potential anti-tumor activity.

  Recruiting Phase 1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Hefei, Anhui and 7 other locations · NCT07730190

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.